WeVote
Log In

Bill

Bill

SB 1211

An Act amending the act of May 17, 1921 (P.L.682, No.284), known as The Insurance Company Law of 1921, in casualty insurance, further providing for coverage for biomarker testing.

2025-2026 Regular Session Introduced by Dave Argall and 16 co-sponsors

Pennsylvania bill mandates insurance coverage for biomarker testing to improve access to diagnostic tests critical for early disease detection and personalized treatment.

Referred to Human Services
0
WeVote Research Nonpartisan
Bill Summary · SB 1211

Legislative bill overview

SB 1211 amends Pennsylvania's Insurance Company Law to expand casualty insurance coverage requirements for biomarker testing. The bill mandates that insurers provide coverage for biomarker tests, which are medical tests that identify biological markers indicating disease risk, presence, or progression. This represents an update to insurance regulations to address modern diagnostic practices.

Why is this important

Biomarker testing has become increasingly critical for early disease detection, personalized treatment planning, and preventive medicine, but inconsistent insurance coverage creates barriers to patient access. Many patients currently face out-of-pocket costs or coverage denials for these tests, which can range from hundreds to thousands of dollars. Mandating coverage could improve early detection outcomes while potentially reducing long-term healthcare costs through prevention.

Potential points of contention

  • Cost implications: Insurance companies will argue that mandated coverage increases premiums and operational costs, while advocates counter that early detection reduces expensive emergency and advanced-stage treatments
  • Medical necessity standards: Ambiguity over which biomarker tests qualify for coverage—dispute over whether all tests should be covered or only those meeting specific clinical evidence thresholds
  • Scope definition: Questions about whether "biomarker testing" includes experimental, investigational, or emerging tests versus established clinical diagnostics, potentially affecting insurance predictability

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.